- Fecal Incontinence
|Positioning biologics and small molecules in the management of moderate to severe ulcerative colitis
Curr Opin Gastroenterol. 2021 Jul 1;37(4):344-350.doi: 10.1097/MOG.0000000000000738.
Bincy Abraham 1 2 3, Kerri Glassner 1 2 3
1Houston Methodist Gastroenterology Associates, Houston, Texas.
2Weill Cornell Medical College, New York, New York.
3Houston Methodist Academic Institute, Houston, Texas, USA.
Purpose of review: This review addresses the selection of biologic and small molecule therapy for patients with moderate to severe ulcerative colitis (UC). With several new treatment options approved within the past few years, an update in positioning is timely and relevant.
Recent findings: Updates on the safety and comparative efficacy of approved therapeutic agents for UC are presented. Newly approved therapies including tofacitinib and ustekinumab, as well as where to position these treatments are discussed. Data on the first-ever head-to-head trial of biologic therapy in UC are examined. This review provides an evidence-based overview of the optimal management strategies of patients in both the inpatient and outpatient settings.
Summary: As we move closer towards the goal of personalized therapy for our patients with UC, we hope to better select appropriate and effective treatment options. Newly approved therapies provide us with additional options for management. Future advancements in predictive serologic, mucosal, genetic, and fecal markers can enable us to tailor therapy to an individual patient.